Tuberous Sclerosis News and Research

Latest Tuberous Sclerosis News and Research

Autism linked with disorganized structure of brain's white matter

It's still unclear what's different in the brains of people with autism spectrum disorders (ASDs), but evidence from genetic and cell studies points to abnormalities in how brain cells (neurons) connect to each other. A study at Children's Hospital Boston now provides visual evidence associating autism with a disorganized structure of brain connections, as well as defects in myelin -- the fatty, insulating coating that helps nerve fibers conduct signals and that makes up the brain's white matter.

6 Dec 2011

New book on pediatric stroke and cerebrovascular diseases

Two decades after the first edition, a third edition of the definitive textbook on stroke in children -- Pediatric Stroke and Cerebrovascular Disorders -- has been published by Demos Medical Publishing of New York City.

15 Oct 2011

Afinitor Phase III study on angiomyolipomas associated with TSC meets primary endpoint

A Phase III study of Afinitor (everolimus) tablets in patients with non-cancerous kidney tumors, or angiomyolipomas, associated with tuberous sclerosis complex (TSC) met its primary endpoint of best overall angiomyolipoma response rate, which includes reduction in kidney tumor size and absence of new tumors.

26 Sep 2011

Health Canada approves Afinitor for treatment of brain tumours caused by TSC in children

Families with children suffering from brain tumours caused by an uncommon genetic disorder known as Tuberous Sclerosis Complex (TSC) have new hope with Health Canada's recent conditional approval of a new therapeutic use for the drug Afinitor (everolimus). Afinitor is the first drug therapy approved in Canada for the treatment of brain tumours caused by TSC in patients three years of age and older.

14 Sep 2011

Green tea shows promise against two types of tumors, HHS

A compound found in green tea shows great promise for the development of drugs to treat two types of tumors and a deadly congenital disease. The discovery is the result of research led by Principal Investigator, Dr. Thomas Smith at The Donald Danforth Plant Science Center and his colleagues at The Children's Hospital of Philadelphia.

16 Aug 2011

Novartis Afinitor Phase III trial on tuberous sclerosis meets primary endpoint

Novartis Pharmaceuticals Corporation announced today Phase III trial results that showed more than one-third of patients taking Afinitor tablets experienced a 50% or greater reduction in the size of their subependymal giant cell astrocytomas, non-cancerous brain tumors associated with tuberous sclerosis complex.

8 Jul 2011

Diagnostic delay in women with tuberous sclerosis complex increases mortality risk

Women with tuberous sclerosis complex (TSC) are often misdiagnosed because the condition, commonly recognized in early childhood when it presents with seizures, manifests differently later in life, typically with renal angiomyolipomas - a benign tumor of the kidney - and pulmonary lymphangioleiomyomatosis (LAM) - a rare lung disease that affects almost exclusively women.

30 Jun 2011

FDA approves Afinitor for treatment of progressive neuroendocrine tumors in the pancreas

On Thursday, the U.S. Food and Drug Administration approved Afinitor (everolimus) to treat patients with progressive neuroendocrine tumors located in the pancreas (PNET) that cannot be removed by surgery or that have spread to other parts of the body (metastatic).

7 May 2011

FDA approves Novartis' Afinitor tablets for pancreatic NET treatment

Novartis Pharmaceuticals Corporation announced today that the US Food and Drug Administration approved Afinitor tablets for the treatment of progressive neuroendocrine tumors of pancreatic origin in patients with unresectable, locally advanced or metastatic disease.

6 May 2011

Sirolimus may help treat lymphangioleiomyomatosis in women

An Oregon Health & Science University researcher has co-authored an international study that revealed a drug approved to prevent rejection in organ transplant patients helped treat a rare lung disease in women.

12 Apr 2011

Afinitor plus BSC doubles progression-free survival in patients with advanced pancreatic neuroendocrine tumors

The New England Journal of Medicine (NEJM) published a study today that shows Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival (PFS), or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET).

10 Feb 2011

First blood-based diagnostic test for LAM

Circadian Technologies has announced today that in conjunction with Cincinnati Children's Hospital Medical Center it has begun offering its LAM diagnostic, which is offered as a laboratory test compliant with CAP (College of American Pathologists) /CLIA regulations.

2 Feb 2011

Researchers report gene therapy strategy that improves Beta Thalassemia in mice model

Researchers at Nationwide Children's Hospital report a gene therapy strategy that improves the condition of a mouse model of an inherited blood disorder, Beta Thalassemia.

11 Jan 2011

Cells that give rise to neurons maintain high levels of ROS

For years, the majority of research on reactive oxygen species (ROS) - ions or very small molecules that include free radicals - has focused on how they damage cell structure and their potential link to stroke, cardiovascular disease and other illnesses.

7 Jan 2011

Dutch scientists provide new insights into intestinal cancer through plant study

Dutch scientists have gained important new insights into intestinal cancer from studying a plant. The disease is called Peutz-Jeghers Syndrome, a hereditary disorder where people develop intestinal polyps that turn into malignant tumors.

5 Jan 2011

Everolimus plus tamoxifen delays disease progression in HR+/HER2- metastatic breast cancer

A new study shows that the addition of everolimus (Afinitor® tablets) to the hormonal therapy tamoxifen in patients with hormone-receptor positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer who have been previously treated with an aromatase inhibitor (AI) delays disease progression compared to tamoxifen alone. These results were presented today at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium in San Antonio, Texas.

10 Dec 2010

Comprehensive guide to current practice of intraoperative neurophysiology

A new book entitled "Intraoperative Neurophysiologic Monitoring" has been published by Cambridge University Press, co-authored by Nationwide Children's Hospital Pediatric Neurologists Gloria M. Galloway, MD, and Khaled M. Zamel, MD; Marc R. Nuwer, MD, of UCLA; and Jaime R. Lopez, MD of Stanford University.

20 Nov 2010

Afinitor tablets decrease size of SEGA associated with tuberous sclerosis

The New England Journal of Medicine (NEJM) today published a study that found patients taking Afinitor (everolimus) tablets experienced a decrease in the size of their subependymal giant cell astrocytoma (SEGA), a benign brain tumor associated with tuberous sclerosis (TS).

4 Nov 2010

Autism Consortium begins new therapeutic initiative on Translational Medicine

The Autism Consortium, an innovative Boston area collaboration of researchers, clinicians, funders and families dedicated to catalyzing research and enhancing clinical care for autism spectrum disorders (ASDs), announced that it will begin a new initiative on Translational Medicine and Autism Therapeutics. The new focus was introduced at the Consortium's fifth annual symposium held October 26th, 2010, at Harvard Medical School in Boston.

2 Nov 2010

FDA approves cancer drug Afinitor for treatment of rare genetic disorder

The U.S. Food and Drug Administration approved the cancer drug Afinitor (everolimus) on Friday to treat patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis (TS), a rare genetic disorder. This approval was for treatments of SEGA that can not be treated with surgery.

1 Nov 2010

Tuberous Sclerosis News and Research

Latest Tuberous Sclerosis News and Research

Autism linked with disorganized structure of brain's white matter

New book on pediatric stroke and cerebrovascular diseases

Afinitor Phase III study on angiomyolipomas associated with TSC meets primary endpoint

Health Canada approves Afinitor for treatment of brain tumours caused by TSC in children

Green tea shows promise against two types of tumors, HHS

Novartis Afinitor Phase III trial on tuberous sclerosis meets primary endpoint

Diagnostic delay in women with tuberous sclerosis complex increases mortality risk

FDA approves Afinitor for treatment of progressive neuroendocrine tumors in the pancreas

FDA approves Novartis' Afinitor tablets for pancreatic NET treatment

Sirolimus may help treat lymphangioleiomyomatosis in women

Afinitor plus BSC doubles progression-free survival in patients with advanced pancreatic neuroendocrine tumors

First blood-based diagnostic test for LAM

Researchers report gene therapy strategy that improves Beta Thalassemia in mice model

Cells that give rise to neurons maintain high levels of ROS

Dutch scientists provide new insights into intestinal cancer through plant study

Everolimus plus tamoxifen delays disease progression in HR+/HER2- metastatic breast cancer

Comprehensive guide to current practice of intraoperative neurophysiology

Afinitor tablets decrease size of SEGA associated with tuberous sclerosis

Autism Consortium begins new therapeutic initiative on Translational Medicine

FDA approves cancer drug Afinitor for treatment of rare genetic disorder

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Tuberous Sclerosis News and Research

Latest Tuberous Sclerosis News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in